COX-2 inhibitors might prevent pre-eclampsia

Cyclooxygenase (COX)-2 inhibitor celecoxib reversed early signs of pre-eclampsia in pregnant mice.

Doctor performs an ultrasound in early pregnancy

Pre-eclampsia is characterised by hypertension and proteinuria in late pregnancy and can be life threatening. It is associated with events in early pregnancy resulting in abnormal embryo implantation, but the mechanisms are not well understood. 

US researchers studied a mouse model of pre-eclampsia and found upregulated levels of uterine cyclooxygenase (COX)-2 and interleukin-15 in early pregnancy. This was associated with decreased levels of decidual natural killer cells, known to be essential for normal embryo implantation. 

A single dose of the COX-2 inhibitor celecoxib at the time of implantation reversed these effects, and improved fetal growth and late gestational hypertension in mothers. 

Reporting in JCI Insight (online, 17 March 2016)[1]
, the researchers conclude that COX-2 inhibition in early pregnancy should be explored as a way to prevent pre-eclampsia.

References

[1] Sones JL, Cha J, Woods AK et al. Decidual COX-2 inhibition improves fetal and maternal outcomes in a pre-eclampsia-like mouse model. JCI Insight 2016;1:e75351. doi: 10.1172/jci.insight.75351

Last updated
Citation
The Pharmaceutical Journal, March 2016;Online:DOI:10.1211/PJ.2016.20200909